Create account

Coverage dated October 29, 2026

Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales

Headline from Quartz

Lilly's revenue guidance rises to $91 billion to $92 billion from $85 billion to $87 billion as quarterly sales climb 39%

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

2 articles, oldest first.

  1. Quartz

    Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales (opens Quartz)

    Published

    Quartz's feed description

    Lilly's revenue guidance rises to $91 billion to $92 billion from $85 billion to $87 billion as quarterly sales climb 39%

  2. Investor's Business Daily

    Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound.

Eli Lilly raised its outlook for a third time this year thanks to soaring Zepbound sales | Since Then